Literature DB >> 2959680

Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty.

N Lahlou1, M Roger, J L Chaussain, M C Feinstein, C Sultan, J E Toublanc, A V Schally, R Scholler.   

Abstract

Short term treatment with GnRH agonists has been reported to increase plasma gonadotropin alpha-subunit (Gn alpha) levels while decreasing plasma immunoreactive LH (IR-LH) levels. In this study we examined the effect of D-Trp6-LHRH (LHRH-A) in microcapsules (60 micrograms/kg, im, every 28 days for 1 yr) in 13 girls suffering from precocious puberty. Plasma IR-Gn alpha was measured by RIA; plasma IR-LH and IR-FSH were measured by both polyclonal RIAs and monoclonal immunoradiometric assays (IRMA). Before treatment, basal IR-LH and IR-FSH levels and peak responses to LHRH measured by both RIA and IRMA were similar, and the Gn alpha response paralleled that of LH. After the first injection of LHRH-A, RIA LH levels were significantly higher than pretreatment levels until day 21, while IRMA LH levels transiently increased, but returned to pretreatment levels by day 7 and became lower thereafter (P less than 0.005). Plasma IR-Gn alpha levels increased from days 3-21 (P less than 0.05). After 1.5 months of treatment, basal RIA LH levels remained detectable and not different from pretreatment levels; IRMA LH levels were very low. The mean RIA and IRMA LH responses to LHRH were decreased at 1.5 and 12 months (P less than 0.01). Basal plasma RIA and IRMA FSH levels were similar during treatment (P greater than 0.05) and significantly lower than pretreatment values (P less than 0.01). The mean RIA and IRMA FSH responses to LHRH decreased significantly at 1.5 months (P less than 0.001). After 12 months, both RIA and IRMA FSH responses were increased, but IRMA values were significantly lower than RIA values. A sustained increase in basal Gn alpha values occurred, but there was a tendency for the peak levels after LHRH treatment to decrease, becoming significantly lower than pretreatment peak levels after 1 yr. The chromatographic analysis on Sephadex G-100 of a pool of plasma samples collected during a LHRH test in three children treated for 6 months indicated that IR-Gn alpha coeluted with [125I]Gn alpha. The large discrepancy between RIA and IRMA LH values suggests the secretion of unusual LH molecules which are recognized by RIA but not by IRMA. The sustained release of large amounts of IR-Gn alpha indicates dissociated effects of LHRH-A on alpha- and beta-subunit secretion by the gonadotrophs. The sustained response of Gn alpha to LHRH demonstrates that gonadotroph cell LHRH receptors are still responsive to LHRH during treatment with a LHRH agonist.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959680     DOI: 10.1210/jcem-65-5-946

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Clinical applications of GnRH analogs.

Authors:  G Forti
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

2.  Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.

Authors:  Judit E Horvath; Ana M Bajo; Andrew V Schally; Magdolna Kovacs; Francine Herbert; Kate Groot
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

3.  Characterization of 12 GnRH peptide agonists - a kinetic perspective.

Authors:  Indira Nederpelt; Victoria Georgi; Felix Schiele; Katrin Nowak-Reppel; Amaury E Fernández-Montalván; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

4.  Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men.

Authors:  G Valenti; L Denti; A Banchini; G Ceresini; G P Ceda; W C Westel; A Negro-Vilar
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

Review 5.  Current and future applications of GnRH, kisspeptin and neurokinin B analogues.

Authors:  Robert P Millar; Claire L Newton
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

6.  Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.

Authors:  P Chanson; N Lahlou; A Warnet; M Roger; G Sassolas; J Lubetzi; G Schaison; P Bouchard
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

7.  Characterization of the EM66 Biomarker in the Pituitary and Plasma of Healthy Subjects With Different Gonadotroph Status and Patients With Gonadotroph Tumor.

Authors:  Johann Guillemot; Marlène Guérin; Anne-Françoise Cailleux; Antoine-Guy Lopez; Jean-Marc Kuhn; Youssef Anouar; Laurent Yon
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-22       Impact factor: 5.555

8.  Decoding high Gonadotropin-releasing hormone pulsatility: a role for GnRH receptor coupling to the cAMP pathway?

Authors:  Joëlle Cohen-Tannoudji; Charlotte Avet; Ghislaine Garrel; Raymond Counis; Violaine Simon
Journal:  Front Endocrinol (Lausanne)       Date:  2012-08-31       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.